ArticleJournal of epidemiology2013
Riluzole and prognostic factors in amyotrophic lateral sclerosis long-term and short-term survival: a population-based study of 1149 cases in Taiwan.
Article in Journal of epidemiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 5 syntheses or guidelines pooled it, 95 citations in OpenAlex.
- Prognostic models for amyotrophic lateral sclerosis: a systematic review.Journal of neurology · 2021Pooled it
- Canadian best practice recommendations for the management of amyotrophic lateral sclerosis.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2020Guideline
- Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta-analysis.Journal of neurology · 2020Pooled it
- Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis.International journal of epidemiology · 2017Pooled it
- Clinical and demographic factors and outcome of amyotrophic lateral sclerosis in relation to population ancestral origin.European journal of epidemiology · 2016Pooled it
- Nomogram prediction model for prognosis of patients with amyotrophic lateral sclerosis.BMC neurology · 2026Article
- Demographic, clinical and genetic characteristics of patients with amyotrophic lateral sclerosis from two specialised centres in Austria.Journal of neurology · 2026Article
- Predictive Analysis of Amyotrophic Lateral Sclerosis Progression and Mortality in a Clinic Cohort From Singapore.Muscle & nerve · 2025Article
- The burden of motor neuron diseases in Asia, 1990-2021: temporal patterns and age-period-cohort analyses.Frontiers in neurology · 2025Article
- Factors associated with the time taken for diagnosis of amyotrophic lateral sclerosis (ALS) in Brazil. An online population-based inquiry.Revista de neurologia · 2023Article
- Enteral tube feeding for amyotrophic lateral sclerosis/motor neuron disease.The Cochrane database of systematic reviews · 2023Review
- Factors affecting do-not-resuscitate decisions among patients with amyotrophic lateral sclerosis in Taiwan.PloS one · 2023Article
- Early initiation of riluzole may improve absolute survival in amyotrophic lateral sclerosis.Muscle & nerve · 2022Article
- Intravenous edaravone treatment in ALS and survival: An exploratory, retrospective, administrative claims analysis.EClinicalMedicine · 2022Article
- Factors associated with assisted ventilation use in amyotrophic lateral sclerosis: a nationwide population-based study in Korea.Scientific reports · 2021Article
- Robot-assisted total gastrectomy for gastric cancer in a patient with amyotrophic lateral sclerosis receiving long-term tracheostomy invasive ventilation.International cancer conference journal · 2021Article
- DDX17 is involved in DNA damage repair and modifies FUS toxicity in an RGG-domain dependent manner.Acta neuropathologica · 2021Article
- Administration of Riluzole Oral Suspension During the Different Stages of Amyotrophic Lateral Sclerosis.Frontiers in neurology · 2021Article
- Article
- Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS.Muscle & nerve · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAmyotrophic lateral sclerosis (ALS) is a rare disease in Taiwan; thus, estimation of ALS mortality is difficult. We evaluated factors associated with ALS survival in Taiwan.
methodsThe study enrolled 1149 Taiwanese with a primary diagnosis of ALS during 1999-2008. Follow-up information was available for all patients; mean (SD) duration of follow-up was 2.91 (2.62) years. Medical interventions, including noninvasive positive pressure ventilation (NIPPV), tracheotomy, gastrostomy, and riluzole, were included in time-dependent survival analysis.
resultsOf the 1149 ALS patients, 438 (38.12%) died during follow-up. Mortality in the first year was 16%, which was 13 times (95% CI 11.1-15.2) the age- and sex-standardized rate of the general population in Taiwan. The average annual crude mortality rate was 13.1% (person-years). Factors significantly associated with increased mortality were male sex, advanced age, rural residence, lower economic status, no tracheotomy, and no riluzole treatment. Significant predictors of long-term versus average survival were younger age at diagnosis, being a dependent or receiving social welfare, and NIPPV support. Significant predictors of short-term versus average survival were older age, being employed, no tracheotomy, and no riluzole use.
conclusionsThe results support the use of riluzole to improve ALS survival. Patients who received riluzole and underwent tracheotomy had the best survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.